DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
67	多発性嚢胞腎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03687554 (ClinicalTrials.gov)	October 5, 2018	26/9/2018	Effect of Venglustat in Patients With Renal Impairment	A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function	Healthy Volunteers;Polycystic Kidney, Autosomal Dominant	Drug: Venglustat GZ/SAR402671	Genzyme, a Sanofi Company	NULL	Completed	18 Years	79 Years	All	24	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03687554
(ClinicalTrials.gov)

October 5, 2018

26/9/2018

Effect of Venglustat in Patients With Renal Impairment

A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function

Healthy Volunteers;Polycystic Kidney, Autosomal Dominant

Drug: Venglustat GZ/SAR402671

Genzyme, a Sanofi Company

NULL

Completed

18 Years

79 Years

All

Phase 1

United States